CNS Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2017
Cash & Equivalents	7.2	6.46	0.55	10.06	5	Upgrade
Cash & Short-Term Investments	7.2	6.46	0.55	10.06	5	Upgrade
Cash Growth	11.45%	1077.53%	-94.54%	100.93%	-64.35%	Upgrade
Other Receivables	-	0.88	-	-	-	Upgrade
Receivables	-	0.88	-	-	-	Upgrade
Prepaid Expenses	0.86	1.29	0.84	2.51	2.47	Upgrade
Other Current Assets	0.05	0.02	0.2	-	-	Upgrade
Total Current Assets	8.1	8.66	1.59	12.56	7.48	Upgrade
Property, Plant & Equipment	0.02	0.01	0	0.01	0.02	Upgrade
Long-Term Deferred Charges	-	-	-	-	0.33	Upgrade
Other Long-Term Assets	0.5	0.04	0.1	0.48	0.93	Upgrade
Total Assets	8.62	8.7	1.7	13.05	8.76	Upgrade
Accounts Payable	3.77	2.2	5.83	4.51	1.98	Upgrade
Accrued Expenses	-	-	-	-	0.22	Upgrade
Short-Term Debt	0.33	0.33	0.3	0.41	0.39	Upgrade
Total Current Liabilities	4.1	2.52	6.13	4.92	2.59	Upgrade
Total Liabilities	4.1	2.52	6.13	4.92	2.59	Upgrade
Common Stock	0	0	0	0	0	Upgrade
Additional Paid-In Capital	104.8	90.6	65.13	58.85	41.6	Upgrade
Retained Earnings	-100.28	-84.42	-69.57	-50.72	-35.44	Upgrade
Shareholders' Equity	4.52	6.18	-4.43	8.13	6.16	Upgrade
Total Liabilities & Equity	8.62	8.7	1.7	13.05	8.76	Upgrade
Total Debt	0.33	0.33	0.3	0.41	0.39	Upgrade
Net Cash (Debt)	6.87	6.14	0.25	9.65	4.62	Upgrade
Net Cash Growth	12.02%	2374.76%	-97.43%	108.92%	-66.05%	Upgrade
Net Cash Per Share	15.50	192.79	-	-	-	Upgrade
Filing Date Shares Outstanding	0.81	0.25	-	-	-	Upgrade
Total Common Shares Outstanding	0.63	0.12	-	-	-	Upgrade
Working Capital	4	6.13	-4.54	7.64	4.88	Upgrade
Book Value Per Share	7.15	52.43	-	-	-	Upgrade
Tangible Book Value	4.52	6.18	-4.43	8.13	6.16	Upgrade
Tangible Book Value Per Share	7.15	52.43	-	-	-	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.